Advent Technologies (ADN) Registration Filing summary

Company overview and business model

• Operates in the advanced materials and hydrogen fuel cell technology sector, focusing on high-temperature proton exchange membrane (HT-PEM) technology with applications in stationary power, heavy-duty mobility, and portable power markets.

• Core business includes developing and manufacturing Membrane Electrode Assemblies (MEA) and fuel cell stacks, with a strategy to license technology to OEMs and Tier 1 manufacturers.

• Revenue streams include engineering and license fees from joint development agreements (JDAs), MEA sales, and fuel cell system sales, with a focus on high-margin licensing as mass production scales.

• Strategic partnerships with major industry players such as Airbus, Hyundai, and the US Army, and significant R&D collaborations with US Department of Energy labs.

• Holds approximately 150 patents and is expanding manufacturing capacity in the US and Greece, supported by EU and US government grants.

Financial performance and metrics

• For the six months ended June 30, 2025, revenue was $0.2M, down from $3.4M in the prior year period, with a net loss of $7.1M from continuing operations.

• As of June 30, 2025, cash and cash equivalents were $0.1M, with a working capital deficit of $27.8M and total liabilities of $36.1M.

• Operating cash outflows for the first half of 2025 were $1.2M, with negative cash flow from operations and a substantial doubt about the ability to continue as a going concern.

• Annual revenue for 2024 was $3.3M, with a net loss of $41.0M, and accumulated deficit of $227.2M as of June 30, 2025.

• Gross margins remain negative, and the company continues to rely on external financing and grant income.

Use of proceeds and capital allocation

• May receive up to $52M in gross proceeds from sales of common stock to Hudson Global under a 24-month equity purchase agreement, at the company's discretion.

• Proceeds are intended for operating and capital expenses, including investments in production equipment, automation, facility expansion, hiring, and general corporate purposes.

• No specific allocation percentages disclosed; proceeds may also support projects of the Greek subsidiary and general working capital.